Edwards Lifesciences Raises 2026 Guidance After 13.6% Q2 Sales Growth

Edwards Lifesciences reported second-quarter 2026 sales of $1.74 billion for the quarter ended June 30, up 13.6% from a year earlier, with diluted EPS of $0.42 and adjusted EPS of $0.78; TMTT sales rose 47.7% to $198.6 million and TAVR sales increased 11.3% to $1.26 billion. On July 23, the company raised its 2026 total sales growth guidance to 10%-11% from 9%-11%, TAVR growth guidance to 8%-9%, and TMTT sales guidance to $760 million-$780 million, while reaffirming adjusted EPS guidance of $2.95-$3.05; GAAP results included a $188.2 million tax charge related to California’s R&D credit changes.